TheraRadar
Data updated: May 26, 2026

CEFTRIAXONE SODIUM

Trial Activity: Declining 3 active trials
Infectious Disease Approved 2017-01-20

CEFTRIAXONE SODIUM is indicated for the treatment of Lower Respiratory Tract Infection; Acute Bacterial Otitis Media.

Source: FDA Label • ANDA REPOSITORY

Development Insights

Assistance Publique - Hôpitaux de Paris conducting 3 trials (8%)
48 indications explored (Broad Platform)
gonorrhea (4 trials)
gonococcal infection (2 trials)
infection (2 trials)
2
Indications
--
Phase 3 Trials
9
Years on Market

Details

Status
Prescription
First Approved
2017-01-20
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: CEFTRIAXONE SODIUM

CEFTRIAXONE SODIUM Approval History

2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
4 FDA actions from 2017 to 2022
Jan 2022 SUPPL
Label · Labeling
Oct 2017 ORIGINAL
Update
Jan 2017 ORIGINAL
Update

What CEFTRIAXONE SODIUM Treats

2 indications

CEFTRIAXONE SODIUM is approved for 2 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Lower Respiratory Tract Infection
  • Acute Bacterial Otitis Media
Source: FDA Label

CEFTRIAXONE SODIUM Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CEFTRIAXONE SODIUM

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMOXICILLIN PEDIATRIC
AMOXICILLIN
2 shared
Teva
AUGMENTIN '125'
AMOXICILLIN
2 shared
US ANTIBIOTICS
AUGMENTIN '250'
AMOXICILLIN
2 shared
US ANTIBIOTICS
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT04975945 generalsurgery/2021/01 Ph 4 withdrawn Assessing Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration for Prevention of SSI
NCT01254344 results posted 0826-056 Ph 3 completed Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)
NCT01473836 results posted A6831005 Ph 3 completed A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CEFTRIAXONE SODIUM FDA Label Details

Indications & Usage

CEFTRIAXONE SODIUM is indicated for the treatment of Lower Respiratory Tract Infection; Acute Bacterial Otitis Media.

Looking for the branded version?

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

Full clinical data, patents, trials, and competitive landscape for ceftriaxone sodium.

See CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment